Clinical Trial Detail

NCT ID NCT03880019
Title Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

uterus leiomyosarcoma


Olaparib + Temozolomide

Age Groups: senior adult

No variant requirements are available.